SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Corcept Therapeutics Q3 Earnings and Revenue Rise; Shares Fall After Hours

Corcept Therapeutics reported higher Q3 earnings and revenue. Its shares fell after hours.

CORT
SquawkNews Desk 1 updates Updated Nov 03, 2026, 10:17 PM UTC

Story updates

10:17:01 PM UTC
SquawkNews
Corcept Therapeutics Forecasts 2026 Revenue of $1.1 Billion-$1.2 Billion Corcept Therapeutics fo

Related stories

Spartan Delta Reports Q3 Results, Updates Capital Program and Guidance Spartan Delta announced third-quarter 2026 results, an updated 2026 capital program, 2027 guidance and a higher Duvernay production target. M impact | EQUITY | Nov 03, 2026, 11:04 PM UTC 3M Reaches Broad Resolution of AFFF Personal Injury Litigation M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC 3M to Commit $5.8 Billion Through 2034 to Resolve Injury Claims 3M says it will make a $5.8 billion present-value commitment through 2034 to resolve multidistrict personal injury claims, substantially reducing litigation risk and uncertainty. M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC Flywire Reports Q3 2026 Results, Raises Growth and Margin Guidance Revenue rose 25.1% year over year to $250.3 million, above FactSet consensus of $233.3 million. EPS was $0.57 versus $0.31 expected; adjusted EBITDA increased 39.2%. M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC Ouster Reports $59 Million in Third-Quarter 2026 Revenue Ouster said it shipped more than 27,000 sensors and forecast fourth-quarter revenue of $61.0 million to $64.0 million. Revenue exceeded analyst expectations of $56.3 million; Stere M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC Seadrill Reports Q3 2026 Revenue of $428 Million, Raises Guidance Seadrill reported a $0.49 per-share loss, versus consensus earnings of $0.19 per share. Revenue was $428.0 million, above the FactSet estimate of $382.7 million. M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC